13F Data
13F filer · CIK 1553936

TYBOURNE CAPITAL MANAGEMENT (HK) LTD

HONG KONG, K3 · filing since Q2 2013 · last filing Nov 6, 2025
Reported value
$30.9M
$-3.6M vs prior
Positions
4
New / sold out
0 / 2
Added / reduced
0 / 2
Turnover
0.0%
buys $0 · sells $11.1M
Top-10 weight
100.0%

Biggest buys vs Q2 2025

No new or increased positions this quarter.

Biggest sells vs Q2 2025

ChangeSecurityShares changeChange %Est. trade value
Sold outBICYCLE THERAPEUTICS LTD-ADR (BCYC US)-993,743-100.0%$-6.9M
Sold outMALIBU BOATS INC (MBUU US)-66,705-100.0%$-2.1M
ReducedTAYSHA GENE THERAPIES INC (TSHA US)-395,000-9.6%$-1.3M
ReducedZENTALIS PHARMACEUTICALS INC (ZNTL US)-516,666-35.0%$-780.2K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q2 2013: $671.4MQ3 2013: $842.5MQ4 2013: $915.4MQ1 2014: $878.0MQ2 2014: $1.1BQ3 2014: $1.0BQ4 2014: $1.1BQ1 2015: $1.1BQ2 2015: $1.2BQ3 2015: $1.4BQ4 2015: $1.3BQ1 2016: $1.5BQ2 2016: $1.9BQ3 2016: $2.0BQ4 2016: $2.1BQ1 2017: $2.2BQ2 2017: $2.2BQ3 2017: $1.3BQ4 2017: $1.6BQ1 2018: $2.0BQ2 2018: $2.2BQ3 2018: $2.3BQ4 2018: $2.2BQ1 2019: $2.6BQ2 2019: $2.8BQ3 2019: $2.3BQ4 2019: $2.6BQ1 2020: $2.7BQ2 2020: $3.3BQ3 2020: $4.1BQ4 2020: $4.8BQ1 2021: $4.6BQ2 2021: $4.7BQ3 2021: $4.0BQ4 2021: $3.4BQ1 2022: $1.7BQ2 2022: $1.4BQ3 2022: $1.0BQ4 2022: $1.0BQ1 2023: $993.2MQ2 2023: $925.3MQ3 2023: $715.7MQ4 2023: $671.2MQ1 2024: $584.9MQ2 2024: $491.7MQ3 2024: $356.7MQ4 2024: $398.4MQ1 2025: $23.6MQ2 2025: $34.5MQ3 2025: $30.9M
Q2 2013Q3 2025

Holdings · Q3 2025

#SecuritySharesValueWeight
1TAYSHA GENE THERAPIES INC (TSHA US)COM SHS3,700,000$12.1M39.11%
2FORTE BIOSCIENCES INC (FBRX US)COM NEW786,647$11.8M38.15%
3ALUMIS INC (ALMS US)COM1,399,250$5.6M18.05%
4ZENTALIS PHARMACEUTICALS INC (ZNTL US)COM961,486$1.5M4.69%